| The said facility manufactures oral solid dosage forms. The EIR was issued post the last inspection of the facility conducted in July 2023. The USFDA has determined that the inspection classification of the facility is voluntary action indicated (VAI). Nilesh Gupta, managing director, Lupin, said, ?We are pleased to receive the EIR with a VAI status from the U.S. FDA for the recent inspection of our Nagpur Unit-1 facility. This achievement underscores our commitment to quality and compliance and also mirrors our core values, reaffirming our commitment to providing high-quality healthcare solutions to our patients around the world.? Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The company reported consolidated net profit of Rs 452.26 crore in Q1 FY24 as compared with net loss of Rs 89.08 crore in Q1 FY23. Revenue from operations jumped 31.58% YoY to Rs 4,742.12 crore in Q1 FY24. Powered by Capital Market - Live News |